Sugi Predict

Sugi Predict / Compounds / SCHEMBL600598

SCHEMBL600598

SCHEMBL600598

Cc1c(N)cc(Br)cc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.66
▸ KMT2A Q03164 3/20 0.66
▸ MEN1 O00255 2/20 0.66
▸ TDP1 Q9NUW8 2/20 0.66
▸ GLA P06280 1/20 0.55
▸ AKR1C3 P42330 3/20 0.47
▸ AKR1C2 P52895 2/20 0.47
▸ AKR1C1 Q04828 2/20 0.47
▸ AKR1C4 P17516 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.46
▸ MAPT P10636 4/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ POLB P06746 2/20 0.44
▸ MYC P01106 1/20 0.42
▸ NR4A1 P22736 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.40
▸ CDC25B P30305 1/20 0.40
▸ CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27556655 0.85 AKR1C3 (0.56) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL13468056 0.84 KDM4E (0.46) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL6777970 0.80 AKR1C3 (0.47) KDM4EKMT2AMEN1TDP1GLA
Bromobenzene SCHEMBL27997726 0.80 AKR1C3 (0.51) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL29920315 0.79 KDM4E (0.47) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL22055395 0.79 KDM4E (0.42) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL12499964 0.79 KDM4E (0.47) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL2226763 0.79 AKR1C3 (0.61) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL30505691 0.79 KDM4E (0.59) KDM4EKMT2AMEN1TDP1GLA
SCHEMBL11798181 0.79 KDM4E (0.59) KDM4EKMT2AMEN1TDP1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116655612-A Synthetic method and application of EZH2 inhibitor 王亚男 2023-08-29 — — CN claimed
CN-122071475-A Ternary condensed ring derivative and medical application thereof 杭州百新生物医药科技有限公司 2026-05-22 — — CN disclosed
EP-4628483-A1 DIHYDROPHTHALAZINE-CONTAINING COMPOUND Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2025-10-08 — — EP disclosed
CN-117049963-A Preparation method of 5-bromo-3-fluoro-2-methylbenzoate 上海泰坦科技股份有限公司 2023-11-14 — — CN disclosed
CN-116655612-A Synthetic method and application of EZH2 inhibitor 王亚男 2023-08-29 — — CN disclosed
CN-109745316-B Combination therapy for the treatment of cancer EPIZYME股份有限公司 2023-01-24 — — CN disclosed
CN-112341390-B Compound for preparing targeted histone methyltransferase EZH2 covalent inhibitor and preparation method and application thereof 四川大学 2022-08-23 — — CN disclosed
CN-108358899-B Salt forms of human histone methyltransferase EZH2 inhibitor EPIZYME股份有限公司 2021-07-27 — — CN disclosed
CN-112341390-A Compound for preparing targeted histone methyltransferase EZH2 covalent inhibitor and preparation method and application thereof 四川大学 2021-02-09 — — CN disclosed
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2019-11-19 — — US disclosed
US-20150126522-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-05-07 — — US disclosed
US-20150126522-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-05-07 — — US disclosed
US-20140256700-A1 CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-09-11 — — US disclosed
WO-2014134232-A1 CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-04 — — WO disclosed
US-8722687-B2 Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy ASTEX THERAPEUTICS LTD (GB) 2014-05-13 — — US disclosed
WO-2013173441-A2 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-11-21 — — WO disclosed
WO-2012142513-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2012-10-18 — — WO disclosed
EP-2419428-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY Astex Therapeutics Ltd. (GB) 2012-02-22 — — EP disclosed
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-02-16 — — US disclosed
WO-2010119285-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2010-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041000-A1 IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY FGFR1, FGFR3, FGFR2 KDM4E 1289/4885KMT2A 1043/4885MEN1 2623/4885
US-20140256700-A1 CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS BRD3, BRD4, BRPF3 KDM4E 975/4885KMT2A 272/4885MEN1 2760/4885
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors EZH2, EZH1, BMI1 KDM4E 43/4885KMT2A 18/4885MEN1 673/4885
US-20150126522-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 KDM4E 42/4885KMT2A 25/4885MEN1 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.